DBS Safe But Not Beneficial in Parkinson's Dementia

Share this content:
DBS Safe But Not Beneficial in Parkinson's Dementia
DBS Safe But Not Beneficial in Parkinson's Dementia

TUESDAY, Dec. 19, 2017 (HealthDay News) -- Low-frequency deep brain stimulation of the nucleus basalis of Meynert (NBM DBS) can be safely conducted in patients with Parkinson's disease dementia, but it does not result in significant improvements in primary cognitive outcomes, according to a study published online Dec. 18 in JAMA Neurology.

James Gratwicke, M.D., Ph.D., from University College London, and colleagues evaluated six patients with Parkinson's disease dementia who were treated with NBM DBS. After surgery, patients received either active stimulation (bilateral, low-frequency [20 Hz] NBM DBS) or sham stimulation for six weeks followed by the opposite condition for the next six weeks.

The researchers found that all patients tolerated surgery and stimulation well with no reports of serious adverse events. There were no consistent improvements in primary cognitive outcomes or in resting state functional magnetic resonance imaging results. NBM DBS patients saw an improvement in Neuropsychiatric Inventory scores versus sham stimulation (8.5 versus 12 points).

"Low-frequency NBM DBS was safely conducted in patients with Parkinson disease dementia; however, no improvements were observed in the primary cognitive outcomes," the authors write. "Further studies may be warranted to explore its potential to improve troublesome neuropsychiatric symptoms."

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

CDC: Birth Rate for 10- to-14-Year-Olds at Record Low in 2016

CDC: Birth Rate for 10- to-14-Year-Olds at Record ...

Reduction in birth rates for all race and Hispanic origin groups; largest decline in non-Hispanic blacks

Lonafarnib May Lower Mortality in Hutchinson-Gilford Progeria

Lonafarnib May Lower Mortality in Hutchinson-Gilford Progeria

Lower mortality seen with lonafarnib monotherapy after 2.2 years compared with no treatment

About 40 Percent of Men Report Experiencing Weight Stigma

About 40 Percent of Men Report Experiencing Weight ...

Experience of weight stigma associated with increased odds of underweight or obesity

is free, fast, and customized just for you!

Already a member?

Sign In Now »